Revenue
Margin
Demand
Guidance
Tone
Metrics cut 1
- Contrast media launch timeline delayed by two quarters for R&D fine-tuning; still targeted for H2 FY27 (prior guidance expected earlier in FY27)
Event Participants
Executives
3
Krishna Raghunathan, Saloni Satish Wagh, Shivani Satish Wagh
Analysts
12
Abhishek, Achal Maheshwari, Adityapal Singh Jaggi, Jason, Miten Shah, Mulesh Savla, Nikhil Upadhyay, Nirmam Mehta, Rachna Kukreja, Rishabh Tripathi, Saloni Singh, Tushar Bohra
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Revenue from Operations | ₹190 crores | +31% YoY vs ₹145 crores Q1 FY26; ~₹35 crores of sales deferred due to water shortage |
| EBITDA | ₹47 crores | -8.1% YoY vs ₹52 crores; ~₹10.5 crores additional costs from power/solvent/water headwinds |
| EBITDA Margin | 25% | Down ~10.5pp YoY; excluding one-off impacts, within guided 33–35% range |
| PAT | ₹24 crores | -31.4% YoY vs ₹35 crores Q1 FY26 |
| PAT Margin | 12.7% | Dragged by margin compression and one-off costs |
| Capex (Q1 FY27) | ₹16.58 crores | Spend on maintenance, small projects, formulation plant requirements, and ISAMB land |
| Backward Integration | 72% of revenue | Continued progress on integration strategy |
| Export Contribution | 81% of revenue | Asia 39%, Europe 35%, Latam 20% of exports |
| Cash Reserves | ~₹150 crores | In FDs and mutual funds; earmarked for ISAMB project phase 1 |
| Inventory | ₹230–240 crores | Elevated due to planned maintenance shutdown inventory build; to be liquidated over next 3–4 quarters |
| Working Capital Utilization | Nil (except LC/BG) | No working capital limits drawn for the year |
Geographic & Segment Commentary
- Exports: 81% of revenue with Asia contributing 39%, Europe 35%, and Latam 20%. North America saw sequential improvement driven by four to five new US DMF filings with customers picking up validation volumes; management expects this momentum to continue as new products scale. Europe remained slower during the quarter, which contributed to margin mix pressure.
- Domestic & Semi-Regulated Markets: Cardiovascular advanced intermediate launched in Q3 FY26 has commercialized with good traction from domestic and semi-regulated markets; anesthetic API seeing demand from Korea and Taiwan, with CEP filing expected to be received between October–November to boost regulated market sales.
- New Product Portfolio: Two anesthetic liquid inhalation products launched commercially in Q2 FY27 from Ambarnath; two ADHD products in pipeline; contrast media launch on track for H2 FY27 (delayed two quarters for R&D fine-tuning and cost competitiveness); DSM contract reached near-peak volumes with pharma validation completed.
Company-Specific & Strategic Commentary
- CDMO/CMO Growth Vertical: Close to signing a term sheet for a large anesthetic CDMO contract with an innovator, expected to be announced next quarter; five to six additional APIs and advanced intermediates at initial discussion stages; Ambarnath positioned as predominantly CMO/CDMO-driven site with two launched formulations and five to six pipeline products (tablets, injectables) attracting European and North American collaboration interest. Management expects CMO/CDMO to become one of the company's strongest verticals in 3–4 years.
- Ambarnath Regulatory Milestone: EU audit scheduled for second half of November; will unlock regulated market ramp-up for finished formulations and two commercially launched anesthetic products.
- Patal Ganga (ISAMB) Facility: Construction commenced with boundary walls in progress; total ₹200 crores capex earmarked; API blocks prioritized first given Lote capacity approaching exhaustion, followed by formulation blocks in phase 2; ~2.5 years for 40% completion per MIDC requirements.
- Digital & Process Strengthening: SAP implementation scheduled to go live in next 4–5 months; quality management systems, automation at site level, and dedicated CMO/CDMO team under Dr. Shirish Ambar; R&D headcount grown from ~20–30 to ~70 people over two years with new formulation R&D at Ambarnath; Ecovadis silver rating achieved.
- Revised Maintenance Shutdown: Annual maintenance shutdown for Blocks A–D deferred from a full August shutdown to phased debottlenecking to avoid Q2 FY27 production impact.
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| Revenue | ~₹1,000 crores for FY27 | Confirmed on track; ~₹25–35 crores Q1 sales loss to be recovered in coming quarters on purchase-order basis; growth expected nonlinear across quarters |
| EBITDA Margin | 33–35% for FY27 | Excluding one-off Q1 impacts (water, solar policy, solvent costs), margins within guided range; ongoing cost increases to be passed on to customers |
| Long-Term Growth | ~20% CAGR | Potential to exceed 20% driven by new products, formulations, CDMO vertical, and capacity additions; dependent on regulatory approval timelines |
| Contrast Media | Launch in H2 FY27 | On track; R&D finalizing technology to be cost-competitive in generic market |
| EU Audit | November (second half) | Ambarnath audit scheduled; will enable regulated market ramp-up |
| Patal Ganga Phase 1 | API-first development | First focus on API blocks; formulation in phase 2; 40% completion in ~2.5 years |
Risks & Constraints
| Risk | Context |
|---|---|
| Customs/Legal Matter (Psychotropic Drug Export) | One consignment under investigation due to a two-day technical lapse in export authorization renewal; matter subjudice with one employee in judicial custody; new CBN export authorization received which management believes will regularize the export; no provision made; limited to a single low-value consignment, no cascading effect on other exports |
| Water Scarcity Recurrence | First-ever water shortage at Lote MIDC (Koyna River supply) caused ~15–20 days of production loss and ~₹35 crores deferred sales; resolved with monsoon; management engaging consultants to improve water recycling for utility purposes (cooling towers), though API manufacturing cannot use recycled water in final products |
| Regulatory Approval Dependency | Heavy reliance on regulatory approvals (80%+ revenue from exports, large chunk from regulated markets) for new product scale-up; any delays in CEP, EU audits, or DMF approvals will push revenue contribution timelines |
| North America Tariff Risk | Potential 100% tariff on pharma products flagged for future; current exposure minimal as Europe and Latam dominate; management sees Europe remaining the larger market even as North America grows with new launches |
| Power Cost Policy Change | Maharashtra solar power policy revision resulted in ₹8 crores additional costs in Q1 (~₹4.5–5 crores retrospective); industry case filed against MSEDCL; ongoing price increases to be passed on to customers |
Q&A Highlights
Patal Ganga Timeline & Strategic Focus
- Question: Why the delay in breaking ground at Patal Ganga given block F at Lote needs to complete by FY29-30 and greenfield pharma takes 3-4 years? (Adityapal Singh Jaggi, MSA Capital Partners)
- Answer: Construction has already started with boundary walls; API blocks prioritized first given Lote capacity nearing exhaustion, formulations in phase 2; ~2.5 years to 40% completion per MIDC. Minor refurbishments at Lote will further enhance capacity. (Krishna Raghunathan, Saloni Satish Wagh)
Water & Solar Power Cost De-risking
- Question: What long-term measures for water de-risking and is the solar subsidy a one-time or recurring cost? (Nikhil Upadhyay, SiMPL)
- Answer: Water shortage was first-time in the region (normally highest rainfall in Maharashtra); consultants engaged for water recycling in utilities (cooling towers) though not in final API product. Solar subsidy includes ~₹4.5–5 crores retrospective collection for March–July; industry association has filed a case against MSEDCL; ongoing price increases will be passed to customers. (Krishna Raghunathan, Saloni Satish Wagh)
Contrast Media Development Driver
- Question: How is the company managing closed-loop specification challenges with the few contrast media formulators, and will it be non-regulated only? (Nikhil Upadhyay, SiMPL)
- Answer: Combination of API for semi-regulated markets and finished formulation tie-ups at Ambarnath; launch delayed two quarters primarily for R&D fine-tuning on technology to achieve cost competitiveness in a generic market; exploring alternate process/technology to protect margins. (Saloni Satish Wagh)
Guidance Reconfirmation & Q2 Cost Outlook
- Question: With ₹10.5 crores one-off costs, can management reconfirm full-year guidance and give Q2 cost visibility? (Mulesh Savla, Shah & Savla LLP)
- Answer: Water issue resolved (15–20 days impact only); power retrospective cost will not recur in Q2; raw material/solvent price increases will be passed on through purchase-order pricing. Company confident of recovering the ~₹25–35 crores lost sales in coming quarters and achieving ~₹1,000 crores revenue with 32–35% EBITDA margin. (Saloni Satish Wagh)
Customs Matter Details
- Question: Has a provision been made against the customs-flagged sales and why was license renewal missed? (Mulesh Savla, Shah & Savla LLP)
- Answer: No provision made as new CBN export authorization already received for the consignment; matter is a two-day technical lapse where authorization expired before shipping bill was raised—not a license expiry affecting other shipments; every consignment of this psychotropic drug requires separate authorization; matter subjudice in High Court. (Saloni Satish Wagh, Krishna Raghunathan)
CMO/CDMO Progress
- Question: Updates on CMO contracts? (Nirmam Mehta, Unique PMS)
- Answer: Large anesthetic CDMO contract very close to term sheet signing; quality and qualification work completed at back end; announcement expected next quarter. CDMO becoming serious growth vertical with multiple API and advanced intermediate discussions in regulated markets; Ambarnath has launched two finished formulations with five to six more products in pipeline for Europe and North America collaboration. (Saloni Satish Wagh)
DSM and Product Ramp-Up
- Question: Does the vitamin therapy mix improvement indicate DSM ramp-up, and are Ambarnath launches ramping as expected? (Nirmam Mehta, Unique PMS)
- Answer: DSM at very stable state, close to peak volumes; pharma validation completed; dedicated DSM facility up and running. New products ramping well—cardiovascular advanced intermediate commercialized with domestic and semi-regulated traction; anesthetic API seeing demand from Korea/Taiwan with CEP expected October–November; CEP will further boost European market sales. (Saloni Satish Wagh)
Q2 Shutdown Revision & Beyond-FY27 Growth
- Question: What is the impact of the planned Q2 shutdown, and is there FY28 guidance? (Saloni Singh, Investor)
- Answer: Big shutdown cancelled; smaller debottlenecking activities across blocks to avoid major production impact. Beyond FY27, 20% CAGR trend continues with multiple growth drivers—new API additions, new therapies, Ambarnath formulation revenue post-audit, CMO/CDMO collaborations, and Patal Ganga capacity building. (Saloni Satish Wagh)
Tariff Scenario & Cash Position
- Question: Cash reserves and planned capex? What is North America tariff exposure? (Miten Shah, Individual Investor)
- Answer:
₹150 crores in FDs/mutual funds earmarked for ISAMB phase 1 (₹200 crores, larger for phase 2). No current tariff impact on pharma; North America exposure small (3%); Europe remains larger market even as North America grows—future tariff speculation premature. (Krishna Raghunathan, Saloni Satish Wagh)
Key Takeaway
Supriya Lifescience reported Q1 FY27 revenue of ₹190 crores (+31% YoY), but EBITDA fell 8.1% to ₹47 crores (25% margin) as temporary external shocks—water scarcity at Lote MIDC deferring ~₹35 crores of sales, Maharashtra solar policy changes adding ₹8 crores in power costs, and elevated solvent prices—cumulatively added ~₹10.5 crores in one-off costs. Management reaffirmed FY27 guidance of ~₹1,000 crores revenue and 33–35% EBITDA margins, citing full recovery of deferred sales, passing on input cost increases, and a deferred phased maintenance shutdown. Strategy centers on diversifying beyond API into finished formulations at Ambarnath (EU audit scheduled November), building a CDMO/CMO vertical (large anesthetic contract term sheet imminent), progressing the ₹200 crores Patal Ganga facility with API-first development, and scaling recent launches—cardiovascular, ADHD, and liquid anesthetics—across semi-regulated and regulated markets. Watch items include the subjudice customs matter (one employee in judicial custody, no provision made), regulatory approval timelines governing product ramp-up, and potential North America tariff policy, though current exposure there remains minimal. With contrast media on track for H2 FY27 and DSM volumes near peak, the second half is positioned for materially stronger ramp-up, though execution on regulatory milestones and cost pass-throughs will determine delivery of FY27 commitments.